Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response - Wikidata - wikimedia - TriplyDB

Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response

Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response

http://www.wikidata.org/entity/Q34867045

about

The chemokine superfamily revisited Emerging concepts in immunity to hepatitis C virus infection.Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients Anti-HDV IgM as a marker of disease activity in hepatitis delta Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3 Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review.IP-10 can be measured in dried plasma spots in patients with chronic hepatitis C infection.Evaluation of IL-28B polymorphisms and serum IP-10 in hepatitis C infected chimpanzees.Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial.Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response.Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients Plasma interferon-gamma-inducible protein-10 levels are associated with early, but not sustained virological response during treatment of acute or early chronic HCV infection Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C.Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.Challenges in Providing Treatment and Care for Viral Hepatitis among Individuals Co-Infected with HIV in Resource-Limited Settings Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection.Plasma levels of growth-related oncogene (CXCL1-3) associated with fibrosis and platelet counts in HCV-infected patients.The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis.High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C.IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test Association of IL28B Genotypes and Baseline Serum Interferon-γ-Inducible- Protein-10 Levels with Treatment Response in Hepatitis C Virus Patients in China.Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection.Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy.Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes.Impact of Il28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection.Direct, interferon-independent activation of the CXCL10 promoter by NF-κB and interferon regulatory factor 3 during hepatitis C virus infection.The Role of IL28B Genotype Testing in the Era of Direct Acting Antiviral Agents.Syphilis negatively influences the response to hepatitis C virus treatment in an HIV-infected patient.A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.The interferon signaling pathway genes as biomarkers of hepatitis C virus disease progression and response to treatment.Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations.

P2860

Q26824492-B53C9586-5E55-42F7-8D91-E65C929AFD14 Q27002588-3D8EC2A9-170C-4195-B7F5-C9642FC8A497 Q28539645-A55A9F1A-A394-4EA3-89DC-104B2506D6C6 Q28541284-EE21FECB-1822-46D0-ADC1-6EEC5C540CC4 Q28732828-5E37DBFC-489E-435D-8DD5-9F9E50B9F708 Q30365599-87DEA32A-BB5C-434E-836B-35A0CD8EAE8D Q33706737-86A3B5E6-72C9-41F6-B2D6-7B1D3B58C516 Q34425282-516DC327-9819-4BD1-87E3-FB6D754D8B9D Q34464406-5CDCE35A-F03C-465D-9E9F-BA8D2E088B52 Q34539324-065892CD-D8F2-480A-8337-BCBA9863C8AA Q34717544-F2B9D7FD-1F34-4B8B-92BE-F2A5A0A4EBDA Q34744383-5356C846-DA68-4F3F-A9F8-C667A6884B3E Q34974790-1C0AA936-12A5-4432-B37D-6C852835CE4A Q34981566-7603FD19-6537-4E79-87EF-668D788641BD Q35053399-B0978CF4-4135-4250-BB35-825561F7474F Q35508148-CDB07A8F-8DED-45BA-8FE2-C81130E8492C Q35610571-2257DBB2-38EB-49CC-9813-CBB6C18E7233 Q35675852-AFC05FFE-1B7F-4052-8D25-E93EA649FE58 Q35693436-10E216A7-0258-4A4B-B777-97B324D9C75A Q35764450-903A8125-57A4-41C9-8FBE-95C2AA0C70DE Q35866994-5992F2CD-1E5C-4D0B-9A0A-9529305A8D2B Q36109002-EC38EB9C-0B24-45E9-974A-30AA7B41B1B3 Q36118056-107CF3EC-7402-4302-9199-CFF9C9F007A9 Q36155389-6C37DBAA-AE0C-4EDF-AD70-427972DAF315 Q36224697-B644AF95-AFD5-44C3-9E6C-26AAE7B1EFF0 Q36554751-E8BEE8E3-017B-4449-83B9-F951DA974733 Q36675098-A27CB3CE-63CC-4EE8-AB81-9449E8B6635A Q36836988-ABB54E65-A556-4FAF-A558-8BDB1FF37120 Q36848968-324453A0-793D-4891-86BE-E0065CAD2EA9 Q36874661-3040AE0D-262B-4163-8140-0023833153F6 Q36988456-F64082E8-6658-46B8-A354-4DBBED7058C8 Q37032096-07B0142D-D906-4D48-B271-7252BAE0A160 Q37188844-5694D29D-79EC-48EB-94C6-BD839D3CEA1A Q37308845-B453D84C-5F72-48D4-8D09-AD354FAF798D Q37547206-08931DA5-9AC4-4BB3-9124-8B941B5D5166 Q37639317-6C7741E9-12B4-4C76-8A6A-BCA52DF3D56E Q37701225-9855796E-ABF5-496F-B246-135B3CB0DF57 Q37992195-A68A0CD0-EBF1-40E5-889C-CB82B208462C Q37997042-32E8B83F-F192-43A8-903C-5D445FA13767 Q38002889-BAA7EFFC-90E5-46AD-BFA7-44CE6FF550C5

P2860

Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response

http://www.wikidata.org/entity/Q34867045

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Quantitation of pretreatment s ...... hepatitis C treatment response

@ast

Quantitation of pretreatment s ...... hepatitis C treatment response

@en

Quantitation of pretreatment s ...... hepatitis C treatment response

@nl

type

label

Quantitation of pretreatment s ...... hepatitis C treatment response

@ast

Quantitation of pretreatment s ...... hepatitis C treatment response

@en

Quantitation of pretreatment s ...... hepatitis C treatment response

@nl

prefLabel

Quantitation of pretreatment s ...... hepatitis C treatment response

@ast

Quantitation of pretreatment s ...... hepatitis C treatment response

@en

Quantitation of pretreatment s ...... hepatitis C treatment response

@nl

P1433

Q34867045-FFDBF13D-C1F4-4A3B-90C2-FA09D861FC85

P1476

Q34867045-18C5277C-40A6-4999-BED5-A13A9C1999E7

P2093

Q34867045-2B8B8ABF-54E6-4EF7-BBDC-AE4F6B43F2CC

Q34867045-4627D278-E54B-4105-B0F8-B24DBA4BA6E2

Q34867045-67A52821-19BD-48D5-A2F5-FCC9E628EB0D

Q34867045-6B3F120E-D79C-462C-9006-571BDF87288A

Q34867045-6B586E6E-EFF9-47F3-9921-5A96C7AEBFEB

Q34867045-6FDE999E-A5C0-4F3E-9323-55685D0A6251

Q34867045-7AD11DB6-7622-495F-A736-CF5DB82BF9A3

Q34867045-95F9CCDC-7F47-40C9-8E6E-AB8D076A9A90

Q34867045-98A75310-CCD0-43DF-B9A1-31D8CC859589

Q34867045-B02F9D47-7CD3-4F63-B2F9-FEB9FD4B5CD4

P2860

Q34867045-12723016-F38E-4869-9992-1ADC91673FDE

Q34867045-16E9251A-8A15-4F1A-962E-5D85C6270FF7

Q34867045-182B5E96-19AE-4CB6-AD08-3CBAEA58D9C9

Q34867045-241DBFDC-01E0-49F9-BBBD-BEA06AA27C41

Q34867045-2CD4C2D2-5931-4880-842C-B37678A69767

Q34867045-2D6CA191-E62A-4357-8879-BB0E5F09C428

Q34867045-32A53F42-95A5-4C87-A820-95A0D13F844D

Q34867045-34902FFF-6EBF-41DC-A997-41A97BA30018

Q34867045-3E2D1E90-59E7-48E4-B5E9-6DEDFA9E96EF

Q34867045-4C9A581B-6F11-4629-9019-052DAC31E1CC

P304

Q34867045-C72DB0EA-DBB0-48E9-BBA9-974F429146C3

P31

Q34867045-5CA700ED-C0CD-46CC-8724-855EE485F176

P356

Q34867045-1B2B0949-0F1B-461E-A2FE-66741514B0EB

P407

Q34867045-FFADF11F-1897-4669-A4BC-C902E812B7FE

P433

Q34867045-54B8D294-5A3D-41BA-880E-041723F49884

P478

Q34867045-50C36AAB-AF69-41B7-9425-D25C3E0977E1

P50

Q34867045-21FD1A91-5D19-4CD5-B722-33C6C0A4D43A

P577

Q34867045-9F831B62-10DE-43F5-A38F-27BE9AFFF882

P5875

Q34867045-69BF40C8-E0EC-4FB1-ADC6-0B73A26F6397

P698

Q34867045-FCF79F42-4F8D-42AF-A39A-18A2618EF80A

P932

Q34867045-31595A24-FFD2-4762-AB2C-96A1E6A07E4E

P356

P1433

P1476

Quantitation of pretreatment s ...... hepatitis C treatment response

@en

P2093

Alexander J Thompson

http://www.w3.org/2001/XMLSchema#string

Annick Scholliers

http://www.w3.org/2001/XMLSchema#string

Charles D Howell

http://www.w3.org/2001/XMLSchema#string

David B Goldstein

http://www.w3.org/2001/XMLSchema#string

Gregory Fanning

http://www.w3.org/2001/XMLSchema#string

Jacques Bollekens

http://www.w3.org/2001/XMLSchema#string

Jama M Darling

http://www.w3.org/2001/XMLSchema#string

Jeroen Aerssens

http://www.w3.org/2001/XMLSchema#string

John G McHutchison

http://www.w3.org/2001/XMLSchema#string

Kevin V Shianna

http://www.w3.org/2001/XMLSchema#string

P2860

IL-28, IL-29 and their class II cytokine receptor IL-28R

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

Association of pretreatment serum interferon inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C

Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C

Interferon signaling and treatment outcome in chronic hepatitis C

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection

P304

14-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.24056

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49773645

http://www.w3.org/2001/XMLSchema#string

P698

21254158

http://www.w3.org/2001/XMLSchema#string

P932

3083026

http://www.w3.org/2001/XMLSchema#string